DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2032)

Multiple Myeloma | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

Multiple Myeloma | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

KEY BENEFITS AND USES

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand who the competition is and how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED

  • Where is my product positioned versus competitors in the treatment journey?
  • What are physicians’ most frequent treatment sequences—who is benefiting and how can I defend my asset’s share and position?
  • What are the market-relevant treatment scenarios according to oncology experts?
  • Where are the untapped business opportunities on which I can capitalize?
  • How can I optimize trial design and ensure a competitive edge for my pipeline asset?

PRODUCT DESCRIPTION

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the patient journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.

GEOGRAPHIES

United States

PRIMARY MARKET RESEARCH

Survey of ~100 U.S. physicians

Table of contents

  • Detailed, Expanded Analysis: Treatment Sequencing (US)
    • Treatment Sequencing Multiple Myeloma US March 2019

Already a Client? Log in to access this report.

  • Pub Date: March 2019
  • Author(s): Sudha Malhotra, Ph.D
  • Sudha is a Senior Research Associate in the Oncology team at Decision Resources Group. She is responsible for performing secondary market research for major pharmaceutical ; Prior to joining DRG, she obtained her doctorate in life sciences from the National Institute of Immunology, New Delhi, India. She holds a in microbiology and a in biomedical sciences both from the University of Delhi, India and has published several peer-reviewed papers.

Purchase Report

Recent reports:
You may also be interested in: